Rocuronium has the most rapid onset of action among the nondepolarizing neuromuscular blocking drugs; doses of 0.6-0.9 mg/ Kg guarantee a complete block in about 60-90 seconds and good or excellent intubating conditions in 60 seconds [1,2].
Its pharmacokinetics and pharmacodynamics can be influenced by different factors as age, inhaled anesthetics, hepatic and renal insufficiency, hypothermia, gender and obesity [3-8].
Rocuronium has been shown to cause less histamine release and cardiovascular instability than benzylisoquinolinum neuromuscular blocking agents such as atracurium and mivacurium , however it can act as an antigen: in our clinical experience three acute reactions occurred after its administration in the same patient.
Published on: Sep 6, 2014 Pages: 13-15
Prof. Pierre Guertin
Laval University, Canada
International Journal of Pharmaceutical Sciences and Developmental Research
Rafal Tomasz Pawliczak
Medical University of Lodz, Poland
Open Journal of Asthma
Osmar Antonio Centurion
Asuncion National University, Paraguay
Global Journal of Medical and Clinical Case Reports
Saint Joseph Hospital , Germany
Journal of Neurology, Neurological Science and Disorders
ReGenera R&D International for Aging Intervention & San Babila Clinic, Milano, Italy
Archives of Clinical Gastroenterology